The Lynx Group

Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma

February 2021, Vol 12, No 1

On December 18, 2020, the FDA approved selinexor (Xpovio; Karyopharm Therapeutics) in combination with bortezomib (Velcade) and dexamethasone for the treatment of adults with multiple myeloma after ≥1 previous therapies. The FDA granted this indication an orphan drug designation.

Selinexor was previously approved in combination with dexamethasone for adults with relapsed or refractory multiple myeloma who have received ≥4 previous therapies, and for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after ≥2 lines of systemic therapy.

The FDA approved the new indication based on data from the BOSTON clinical trial, a randomized, open-label, multicenter, active comparator–controlled study in patients with relapsed or refractory multiple myeloma who had received between 1 and 3 previous therapies. Patients were randomized in a 1:1 ratio to once-weekly selinexor orally, in combination with once-weekly bortezomib subcutaneously and low-dose dexamethasone twice-weekly (SVd) or to the standard twice-weekly bortezomib plus low-dose dexamethasone (Vd) regimen.

The main end point was progression-free survival (PFS). The estimated median PFS was 13.9 months (95% confidence interval [CI], 11.7-not estimable) in the SVd arm versus 9.5 months (95% CI, 7.6-10.8) in the Vd arm (estimated hazard ratio, 0.70; 95% CI, 0.53-0.93).

The most common (≥20%) adverse reactions reported with the SVd arm were nausea, fatigue, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract, and vomiting. Grade 3 or 4 laboratory abnormalities (≥10%) were thrombocytopenia, lymphopenia, hypophosphatemia, anemia hyponatremia, and neutropenia.

Related Articles


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: